CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS
Key facts
- Where
- Lisbon, PortugáliaSee the 2 sites
Where in Portugália
- NMS Research | Cancer Nanomedicine - João Conde's LabLisbon, PortugáliaNo longer taking part
- Unidade Local de Saúde de São JoséLisbon, PortugáliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universidade Nova de Lisboa
- Trial code
- NCT07630246
- Record updated
- 2026. június 5.
- Original description
Lung cancer remains a significant challenge in oncology, with poor prognosis for patients, especially those with advanced-stage disease. The phenomenon of tumor spread through air spaces (STAS) in pulmonary cancer has garnered attention for its association with aggressive tumor behavior and adverse clinical outcomes. Spread through air spaces identification has been highly debatable on scientific community as an important prognostic feature for distant and locoregional recurrence and as a key player in the differential diagnosis and selection of the appropriate treatment. The aim of this study is to unravel the complexities of STAS-positive lung adenocarcinoma (LUAD) diagnosis and treatment options. For that, we intend to (1) isolate primary lung cancer tissues from early-stages lung adenocarcinoma to fabricate organoid in vitro models and (2) evaluate the microRNA (miRNA) profile of tumor and healthy tissue samples. This is a Hybrid (prospective and retrospective) observational clinical study with a nested translational study.Read full original descriptionShow less
UNCOVERING THE GENETIC LANDSCAPE OF LUNG ADENOCARCINOMA: A CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS
Lung cancer remains a significant challenge in oncology, with poor prognosis for patients, especially those with advanced-stage disease. The phenomenon of tumor spread through air spaces (STAS) in pulmonary cancer has garnered attention for its association with aggressive tumor behavior and adverse clinical outcomes. Spread through air spaces identification has been highly debatable on scientific community as an important prognostic feature for distant and locoregional recurrence and as a key player in the differential diagnosis and selection of the appropriate treatment. The aim of this study is to unravel the complexities of STAS-positive lung adenocarcinoma (LUAD) diagnosis and treatment options. For that, we intend to (1) isolate primary lung cancer tissues from early-stages lung adenocarcinoma to fabricate organoid in vitro models and (2) evaluate the microRNA (miRNA) profile of tumor and healthy tissue samples. This is a Hybrid (prospective and retrospective) observational clinical study with a nested translational study.
Inclusion: Patients older than 18 years old; Active early LUAD diagnosis according to the American Joint Committee on Cancer; Signed informed consent or previous consent given for future research.
Exclusion: Previous treatment for LUAD; History of inflammatory bowel disease and autoimmune diseases; History of hepatic disease (including history of alcoholic or viral hepatitis); LUAD patients with other active malignancy(ies); Incapability of understanding the study and/or providing consent; Signed informed consent unavailable.